Work

Synergistic and antagonistic AML cell type-specific responses to 5-AZA-2’-Deoxycytidine and 1-H-D-Arabinofuranosylcytosine

Year: 2014

Type: article

Abstract: Background The search for synergistic drug combinations is critical to the treatment of drug resistant cancers, such as acute myelogenous leukemia (AML), which has 50% to 60% overall survival in children and lower in adults [1]. Conventional treatments include the S phase-specific polymerase II inhibitor 1-h-D-Arabinofuranosylcytosine (ARA-C), but DNA methyltransferase inhibitors such as 5-Aza-2 -deoxycytidine (DAC) also have activity in AML, through DNA genomic demethylation and altered gene expression [2]. Although genome-wide changes in RNA expression associated with DAC and ARA-C are not fully understood [3], characterizing these responses is a critical step to increasing the efficacy of combinatorial therapies that include DAC and ARA-C.

Source: BMC Genomics

DOI: 10.1186/1471-2164-15-s2-p28

Authors: Abeer Abd Elmoneim, Elisabeth Heuston, Daniel H Wai, Timothy Trich, Robert J Arceci